Literature DB >> 21984468

Reliability of adverse symptom event reporting by clinicians.

Thomas M Atkinson1, Yuelin Li, Charles W Coffey, Laura Sit, Mary Shaw, Dawn Lavene, Antonia V Bennett, Mike Fruscione, Lauren Rogak, Jennifer Hay, Mithat Gönen, Deborah Schrag, Ethan Basch.   

Abstract

PURPOSE: Adverse symptom event reporting is vital as part of clinical trials and drug labeling to ensure patient safety and inform risk-benefit decision making. The purpose of this study was to assess the reliability of adverse event reporting of different clinicians for the same patient for the same visit.
METHODS: A retrospective reliability analysis was completed for a sample of 393 cancer patients (42.8% men; age 26-91, M = 62.39) from lung (n = 134), prostate (n = 113), and Ob/Gyn (n = 146) clinics. These patients were each seen by two clinicians who independently rated seven Common Terminology Criteria for Adverse Events (CTCAE) symptoms. Twenty-three percent of patients were enrolled in therapeutic clinical trials.
RESULTS: The average time between rater evaluations was 68 min. Intraclass correlation coefficients were moderate for constipation (0.50), diarrhea (0.58), dyspnea (0.69), fatigue (0.50), nausea (0.52), neuropathy (0.71), and vomiting (0.46). These values demonstrated stability over follow-up visits. Two-point differences, which would likely affect treatment decisions, were most frequently seen among symptomatic patients for constipation (18%), vomiting (15%), and nausea (8%).
CONCLUSION: Agreement between different clinicians when reporting adverse symptom events is moderate at best. Modification of approaches to adverse symptom reporting, such as patient self-reporting, should be considered.

Entities:  

Mesh:

Year:  2011        PMID: 21984468      PMCID: PMC3633532          DOI: 10.1007/s11136-011-0031-4

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  17 in total

1.  Adverse drug event monitoring at the Food and Drug Administration.

Authors:  Syed Rizwanuddin Ahmad
Journal:  J Gen Intern Med       Date:  2003-01       Impact factor: 5.128

2.  Better reporting of harms in randomized trials: an extension of the CONSORT statement.

Authors:  John P A Ioannidis; Stephen J W Evans; Peter C Gøtzsche; Robert T O'Neill; Douglas G Altman; Kenneth Schulz; David Moher
Journal:  Ann Intern Med       Date:  2004-11-16       Impact factor: 25.391

3.  Precision of health-related quality-of-life data compared with other clinical measures.

Authors:  Elizabeth A Hahn; David Cella; Olivier Chassany; Diane L Fairclough; Gilbert Y Wong; Ron D Hays
Journal:  Mayo Clin Proc       Date:  2007-10       Impact factor: 7.616

4.  Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.

Authors:  Donna L Berry; Carol M Moinpour; Caroline S Jiang; Donna Pauler Ankerst; Daniel P Petrylak; Lynne V Vinson; Primo N Lara; Sharon Jones; Mary E Taplin; Patrick A Burch; Maha H A Hussain; E David Crawford
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

5.  Patient-reported medication symptoms in primary care.

Authors:  Saul N Weingart; Tejal K Gandhi; Andrew C Seger; Diane L Seger; Joshua Borus; Elisabeth Burdick; Lucian L Leape; David W Bates
Journal:  Arch Intern Med       Date:  2005-01-24

6.  Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.

Authors:  Ethan Basch; Alexia Iasonos; Tiffani McDonough; Allison Barz; Ann Culkin; Mark G Kris; Howard I Scher; Deborah Schrag
Journal:  Lancet Oncol       Date:  2006-11       Impact factor: 41.316

Review 7.  Patient-reported outcomes and the evolution of adverse event reporting in oncology.

Authors:  Andy Trotti; A Dimitrios Colevas; Ann Setser; Ethan Basch
Journal:  J Clin Oncol       Date:  2007-11-10       Impact factor: 44.544

Review 8.  Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks.

Authors:  Deborah Watkins Bruner; Charlene J Bryan; Neil Aaronson; C Craig Blackmore; Michael Brundage; David Cella; Patricia A Ganz; Carolyn Gotay; Pamela S Hinds; Alice B Kornblith; Benjamin Movsas; Jeff Sloan; Lari Wenzel; Giles Whalen
Journal:  J Clin Oncol       Date:  2007-11-10       Impact factor: 44.544

Review 9.  Cancer symptom assessment instruments: a systematic review.

Authors:  Jordanka Kirkova; Mellar P Davis; Declan Walsh; Eoin Tiernan; Norma O'Leary; Susan B LeGrand; Ruth L Lagman; K Mitchell Russell
Journal:  J Clin Oncol       Date:  2006-03-20       Impact factor: 44.544

Review 10.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

Authors:  Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin
Journal:  Semin Radiat Oncol       Date:  2003-07       Impact factor: 5.934

View more
  78 in total

1.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

Review 2.  Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.

Authors:  Rajshekhar Chakraborty; Surbhi Sidana; Gunjan L Shah; Michael Scordo; Betty K Hamilton; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-28       Impact factor: 5.742

3.  Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE).

Authors:  Edward J Fox; Alberto Vasquez; William Grainger; Tina S Ma; Christian von Hehn; John Walsh; Jie Li; Javier Zambrano
Journal:  Int J MS Care       Date:  2016 Jan-Feb

Review 4.  Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.

Authors:  Donna R Rivera; Patricia A Ganz; Meghan S Weyrich; Hanna Bandos; Joy Melnikow
Journal:  J Natl Cancer Inst       Date:  2018-02-01       Impact factor: 13.506

5.  Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Authors:  Ethan Basch; Bryce B Reeve; Sandra A Mitchell; Steven B Clauser; Lori M Minasian; Amylou C Dueck; Tito R Mendoza; Jennifer Hay; Thomas M Atkinson; Amy P Abernethy; Deborah W Bruner; Charles S Cleeland; Jeff A Sloan; Ram Chilukuri; Paul Baumgartner; Andrea Denicoff; Diane St Germain; Ann M O'Mara; Alice Chen; Joseph Kelaghan; Antonia V Bennett; Laura Sit; Lauren Rogak; Allison Barz; Diane B Paul; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2014-09-29       Impact factor: 13.506

Review 6.  Cancer-related and treatment-related fatigue.

Authors:  Xin Shelley Wang; Jeanie F Woodruff
Journal:  Gynecol Oncol       Date:  2014-10-23       Impact factor: 5.482

7.  Information visualizations of symptom information for patients and providers: a systematic review.

Authors:  Maichou Lor; Theresa A Koleck; Suzanne Bakken
Journal:  J Am Med Inform Assoc       Date:  2019-02-01       Impact factor: 4.497

8.  Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  Tamara P Miller; Yimei Li; Marko Kavcic; Kelly D Getz; Yuan-Shun V Huang; Lillian Sung; Todd A Alonzo; Robert Gerbing; Marla H Daves; Terzah M Horton; Michael A Pulsipher; Jessica Pollard; Rochelle Bagatell; Alix E Seif; Brian T Fisher; Selina Luger; Alan S Gamis; Peter C Adamson; Richard Aplenc
Journal:  Haematologica       Date:  2017-06-22       Impact factor: 9.941

Review 9.  Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2018-06-18       Impact factor: 18.959

10.  Using patient-reported outcome measures as quality indicators in routine cancer care.

Authors:  Angela M Stover; Ethan M Basch
Journal:  Cancer       Date:  2015-11-30       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.